Thomas Moeslinger

Thomas Moeslinger

Auto-generated profile, based on publicly available information

Thomas Moeslinger

Institute of Physiology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2015 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
JPJakub Patryk Piwowarski
Jakub Patryk Piwowarski
AKAnna Karolina Kiss
Anna Karolina Kiss
Sebastian GranicaSebastian Granica
Sebastian Granica
TMThomas Moeslinger
Thomas Moeslinger

3 December 2015 in Journal of Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
CECem Ekmekcioglu
Cem Ekmekcioglu
IEIbrahim Elmadfa
Ibrahim Elmadfa
AMAlexa Meyer
Alexa Meyer
TMThomas Moeslinger
Thomas Moeslinger

1 December 2000 in Life Sciences
Verified
Journal Article
Closed access
RFRoswitha Friedl
Roswitha Friedl
MBMonika Brunner
Monika Brunner
TMThomas Moeslinger
Thomas Moeslinger
PSPaul Gerhard Spieckermann
Paul Gerhard Spieckermann

1 December 2001 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
RFRoswitha Friedl
Roswitha Friedl
TMThomas Moeslinger
Thomas Moeslinger
BKBrigitte Kopp
Brigitte Kopp
PSPaul Gerhard Spieckermann
Paul Gerhard Spieckermann

1 November 2009 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
DSDiethart Schmid
Diethart Schmid
FWFlorian Woehs
Florian Woehs
MSMartin Svoboda
Martin Svoboda
TTTheresia Thalhammer
Theresia Thalhammer
PCPeter Chiba
Peter Chiba
TMThomas Moeslinger
Thomas Moeslinger
Cimicifuga racemosa (black cohosh) is commonly used in traditional medicines as treatment for menopausal symptoms and as an antiinflammatory remedy. To clarify the mechanism of action and active principle for the antiinflammatory action, the effects of aqueous C. racemosa root extracts (CRE) and its major constituents on the release of the proinflammatory cytokines IL-6, TNF-α, IFN-γ, and the chemokine IL-8 were investigated in lipopolysaccharide (LPS)-stimulated whole blood of healthy volunteers. CRE (3 µg/µL and 6 µg/µL) reduced LPS-induced release of IL-6 and TNF-α in a concentration- and time-dependent manner and almost completely blocked release of IFN-γ into the plasma supernatant. Except for IFN-γ, these effects were attenuated at longer incubation periods. IL-8 secretion was stimulated by CRE. As shown by quantitative real-time RT-PCR, effects on cytokines were based on preceding changes in mRNA levels except for IL-8. According to their content in CRE, the phenolcarboxylic compounds caffeic acid, ferulic acid, and isoferulic acid, as well as the triterpene glycosides 23-epi-26-deoxyactein and cimigenol-3-O-xyloside, were tested at representative concentrations. Among these, isoferulic acid was the prominent active principle in CRE, responsible for the observed inhibition of IL-6, TNF-α, and IFN-γ, but not for IL-8 stimulation. The effect of this compound may explain the antiinflammatory activities of CRE and its beneficial actions in rheumatism and other inflammatory diseases.

1 August 1999 in Kidney International
Verified
Journal Article
Closed access
TMThomas Moeslinger
Thomas Moeslinger
RFRoswitha Friedl
Roswitha Friedl
IVIvo Volf
Ivo Volf
MBMonika Brunner
Monika Brunner
HBHalina Baran
Halina Baran
PSPaul Gerhard Spieckermann
Paul Gerhard Spieckermann